Vepesid |
|
 |
|
Vepesid (etoposide) is indicated for use in the treatment of:
1. Small cell carcinoma of the lung.
2. Acute monocytic and myelomonocytic leukaemia.
3. Hodgkin's disease.
4. Non-Hodgkin's lymphoma.
vepesid side effects, vepesid capsules, vepesid injection, vepesid 50, etoposide, etoposide mechanism of action.
Vepesid generic (generic - what is it?)
| Dosage |
Packing |
Price |
Add to basket |
| 50 mg |
8 caps ($11 per caps) |
USD 78.00 |
 |
| 50 mg |
24 caps ($9.7 per caps) |
USD 197.00 |
|
Vepesid: Medications and Prescriptions
Generic name: etoposide
Product Brand Name: Vepesid
Product Manufacturer: Generic version, manufactured in India
Vepesid description
Etoposide phosphate (brand names: Eposin, Etopophos, Vepesid, VP-16) is an inhibitor of the enzyme topoisomerase II. It is used as a form of chemotherapy for malignancies such as Ewing's sarcoma, lung cancer, testicular cancer, lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. It is often given in combination with other drugs. It is also sometimes used in a conditioning regimen prior to a bone marrow or blood stem cell transplant. Chemically it derives from podophyllotoxin, a toxin found in the American Mayapple. Administration It is given intravenously or orally in capsule form. If the drug is given by IV it must be done slowly over a 30 to 60 minute period because it can lower blood pressure as it is being administered. Blood pressure is checked often during infusing with the speed of administration adjusted accordingly.
Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention.
Patients are advised to drink large amounts of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.
Keep etoposide in the container it came in and out of reach of children.
PHARMACOLOGY
In vitro studies suggest that etoposide initially causes metaphase arrest, however this effect appears to be superseded by interference with cell cycle progression before the cell enters mitosis. Cytofluorometic studies using human lymphoblast cell lines have shown that the major delay in cell cycle progression and the maximum cell killing occurs in the S and G2 phases of the cell cycle.
This has been confirmed in several cell lines. The mechanism by which this occurs is unknown but may be related to an inhibition of nucleoside transport demonstrated in HeLa cells. Etoposide does not interfere with microtubule assembly. It is particularly active in human leukaemia cells and a high response rate is also seen in small cell carcinoma of the lung.
Etoposide acts indirectly on cultured HeLa cells and induces single-stranded breaks in DNA. This effect was not demonstrated on DNA in vitro.
INDICATIONS
Vepesid (etoposide) is indicated for use in the treatment of:
1. Small cell carcinoma of the lung.
2. Acute monocytic and myelomonocytic leukaemia.
3. Hodgkin's disease.
4. Non-Hodgkin's lymphoma.
CONTRAINDICATIONS
1. Patients with severe hepatic dysfunction.
2. Patients who have a demonstrated hypersensitivity to any of the ingredients.
3. Severe bone marrow failure (WBC less than 2000 cells/mm3 or platelet count less than 75000 cells/mm3) not due to malignant disease.
Adult:
Intravenous: Intravenously, 50-60 mg/m2/day for 5 days followed by a treatment-free interval of 2-4 weeks.
Total dose should not exceed 400mg/m2 per course.
Vepesid should not be given by rapid intravenous push.
Etoposide should not be mixed with other anti-neoplastic agents in the infusion solution.
Contact with buffered aqueous solutions above pH 8 should be avoided.
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration.
It is important to ascertain that the intravenous catheter is properly positioned during etoposide infusion since extravasation of the drug may cause local irritation.
Vepesid solution should be administered immediately after reconstitution, and certainly within 24 hours, in order to reduce microbiological hazard. Vepesid solution should be stored at room temperature and does not need to be protected from normal room fluorescent light. Vepesid Injection contains no antimicrobial agent. Use once only and discard any residue. Oral Absorption from the oral route is variable (range 17-74% of intravenous dose in one trial, 25-80% in another, the corresponding means being 50 and 53%).
Thus the prediction of the oral dose on the basis of I.V. dosing or on a mg/m2/day basis may be unreliable. Dosages should be titrated to achieve maximum therapeutic effect and to minimise toxicity. The suggested starting dose is approximately 2-3 times that of the intravenous dose, i.e. 100-200mg/m2/day on days 1 to 5. Total dose should not exceed 650mg/m2 per course. Capsules should be taken on an empty stomach.
Vipesid notes:
Vepesid generic name etoposide is used to treat cancer of the testicles, acute monocytic and myelomonocytic leukaemia, Hodgkin's disease and certain types of lung cancer. It is also used to treat some other kinds of cancer in both males and females. Vepesid interferes with the growth of the cancer cells and eventually destroy them.
Vepesid side effects include fast heartbeat, loss of consciousness, shortness of breath, sweating, swelling of face or tongue, tightness in throat, wheezing, unusual tiredness or weakness, black/ tarry stools, blood in urine or stools, cough or hoarseness accompanied by fever or chills, lower back or side pain, painful or difficult urination, pinpoint red spots on skin, sores in mouth or on lips, unusual bleeding or bruising, loss of appetite, nausea, vomiting and temporary loss of hair.
Etoposide mechanism of action results by exerting its anticancer effects by inhibiting the enzyme topoisomerase, which ultimately leads to un-repaired breaks in cellular DNA.
Vepesid injection contains no antimicrobial agent. Use once only and discard any residue. Vepesid capsules absorption is variable. Total dose of Vepesid should not exceed 650mg/m2 per course. It should be administered and consumed under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. If a dose is missed, it is advised to consume it as soon as it is remembered. If it is near the time of the next dose, the missed one should be skip and the usual dosing schedule should be resume.
This medicine can cause birth defects if being used at the time of conception or during pregnancy.
Before taking etoposide makes sure your doctor knows if you are pregnant or if you may become pregnant. Breast-feeding is generally not recommended while you are receiving it.
Store Vesipid at room temperature in the container it came in and out of reach of children.
|
|
Drug category:Drugs to treat lung cancer
 Vepesid
Buy here
|
|
My Basket